Patents by Inventor Hiroaki Mitsuya

Hiroaki Mitsuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acid stable purine dideoxynucleosides
    Patent number: 5495010
    Abstract: Purine nucleosides active against human immunodeficiency virus which are substituted at the 2'-position by a strong electronegative group such as fluorine are stable in an acid environment and thus can be used for oral administration.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: February 27, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, John S. Driscoll, Christopher K-H. Tseng, James A. Kelley, David G. Johns, Hiroaki Mitsuya
  • Lipophilic, aminohydrolase-activated prodrugs
    Patent number: 5459256
    Abstract: The present invention relates, in general, to prodrugs. In particular, the present invention relates to lipophilic, aminohydrolase-activated, anti-viral nucleoside prodrug compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds.
    Type: Grant
    Filed: April 10, 1991
    Date of Patent: October 17, 1995
    Assignee: The Government of the United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, John S. Driscoll, Harry Ford, Jr., James A. Kelley, Joseph J. Barchi, Jr., Hiroaki Mitsuya, Christopher K-H. Tseng, David G. Johns, Joseph E. Tomaszewski
  • Treatment of retroviral induced dementia by administration of 2',3'-dideoxyinosine
    Patent number: 5376642
    Abstract: A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: December 27, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder
  • Method of treating HIV with 2',3'-dideoxyinosine
    Patent number: 5254539
    Abstract: A method for tearing retroviral infections including acquired immune deficiency syndrome (AIDS) with 2',3'-dideoxyinosine or 2',3'-dideoxyadenosine is disclosed. This antiviral effect is irreversible with 2',3'-dideoxyinosine and 2',3'-dideoxyadenosine but reversible with 2',3'-dideoxyguanosine.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: October 19, 1993
    Assignee: U.S. Government, Dept. of Health and Human Services, c/o National Institutes of Health
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
    Patent number: 5026687
    Abstract: A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.
    Type: Grant
    Filed: January 3, 1990
    Date of Patent: June 25, 1991
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder
  • Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
    Patent number: 4935427
    Abstract: Compounds which are active against retroviruses have the following formulaHOH.sub.2 C--CH.dbd.C.dbd.CH--Bwherein B is a purine or pyrimidine heterocyclic ring which is preferably selected from the group consisting of cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, 6-aminopurine, 2,6-diaminopurine, 6-hydroxypurine, 2-amino-6-hydroxypurine, 3-deazapurines, 7-deazapurines, 8-azapurines, and 6-azapyrimidines.
    Type: Grant
    Filed: December 31, 1987
    Date of Patent: June 19, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Samuel Broder, Seiji Hayashi, Hiroaki Mitsuya, Jiri Zemlicka, Shashikant Phadtare
  • Antiviral compositions and methods
    Patent number: 4879277
    Abstract: Compositions containing 2',3'-dideoxycytidine and its triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytophatic effects of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: November 7, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Antiviral compositions and methods
    Patent number: 4861759
    Abstract: Compositions containing 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, and dideoxyguanosine and their triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytopathic effects of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: August 29, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Anti-retroviral compounds
    Patent number: 4837311
    Abstract: A-B-C wherein A and C are each independently 2',3' dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention.
    Type: Grant
    Filed: June 22, 1987
    Date of Patent: June 6, 1989
    Assignees: Hoffman-La Roche Inc., United States of America
    Inventors: Steve Tam, Manfred Weigele, Samuel Broger, Hiroaki Mitsuya
  • Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
    Patent number: 4704357
    Abstract: This invention is an immortalized T-cell clone, designated ATH8, which is highly sensitive to the cytopathic effect of HTLV-III. The ATH8 T-cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or inhibit HTLV-III or related cytopathic retroviruses.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: November 3, 1987
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Anti-retroviral compounds
    Patent number: RE33887
    Abstract: A-B-C wherein A and C are each independently 2',3'dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention.
    Type: Grant
    Filed: November 2, 1990
    Date of Patent: April 14, 1992
    Assignees: Hoffmann-La Roche Inc., United States of America
    Inventors: Steve Tam, Manfred Weigele, Samuel Broder, Hiroaki Mitsuya